ResMed Inc. (RMD) continues to earn the favor of institutional owners, who now hold approximately 69% to 74% of the company. Despite some shares being sold by various entities like Inspire Investing LLC and Confluence Investment Management, others such as Ethic Inc., Pacer Advisors, and State Street Corp have raised their stock holdings in ResMed. The company recently earned FDA clearance for its
AI Smart Comfort CPAP Feature, a development which could shift investment narratives towards ResMed. Financial analysts highlight strong revenues, strategic acquisitions, and strategic innovations in their reports, underlining ResMed's strength as a
growth stock and a robust player in the medical device sector. Conversely, Baird downgraded ResMed to a 'Hold' recommendation due to concerns of slowing growth. Furthermore, ResMed's CEO recently offloaded $1.25 million in shares. However, ResMed has posted successful Q1, Q3, and Q4 earnings reports, outperforming estimates. Overall, ResMed seems well-positioned for the long-term, boasting strong Return on Capital (ROC) and continuous growth.
Resmed RMD News Analytics from Wed, 14 May 2025 07:00:00 GMT to Fri, 02 Jan 2026 13:52:50 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor 2
